The findings confirmed and expanded upon existing literature by demonstrating that the incidence rates of multiple cardiovascular events, including stroke, heart failure, and cardiovascular disease, are significantly higher in patients with narcolepsy.
Mind Moments®, a podcast from NeurologyLive®, brings you exclusive commentary from Alberto J. Espay, MD, PhD, and Anton P. Porsteinsson, MD. [LISTEN TIME: 48 minutes]
Completion of the 12-week program was associated with reported improvements in overall changes in sleep parameters of sleep latency, wake after sleep onset, sleep efficiency, and others.
The phase 1/2a studies are expected to be complete by the end of 2023, with data from the open-label extension studies to be shared in early 2024.
The director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.
In a patient case with tandem occlusion, treatment using the Zoom 88 Support resulted in reduced NIHSS score from 20 to 0.
Differential diagnosis consideration for MS requires a circumspect approach dependent on the clinical presentation and accompanied by vigilance for clinical and paraclinical red flags suggesting alternative diagnoses.
A duo of experts provide insight on various topics related to the advances in treatment options, diagnosis of the disorder, role of genetics, and potential future research and gene therapies.
In comparison with sham, patients on active treatment had higher rates of penumbral tissue salvage and alleviation of hypoperfused ischemic regions.
At 19 weeks, eplontersen-treated patients showed substantial and sustained reductions in serum TTR concentration compared with baseline.
Based on the positive findings, the company intends to submit a new drug application to the FDA before the end of 2023, with regulatory filings in additional markets to follow in 2024.
Although popular at the turn of the century, the use of platform injectable therapies has subsided significantly with the introduction of oral agents, with became the most frequently initiated therapies by 2020.
Several patients have completed the 18-month trial and have moved on to the open-label extension, where they will be followed for an additional 12 months.
With other potential antiamyloid therapies on the way, the proposal would allow for additional coverage of PET scans to check for amyloid-ß, potentially reducing provider and patient burden.
The 52-week, dose-ascending trial will have data read out in the first half of 2024, with long-term safety and efficacy evaluated over a 5-year period following completion of the initial trial.
In total, 33% of the study participants died within 180 days after initiating their first opioid prescription, compared with 6.4% of those unexposed.
In an analysis of more than 2700 patients aged 55 years or older on semaglutide, the therapy demonstrated a safety profile that was similar to that observed in the overall population.
Change in phosphorylated tau231, the primary outcome, favored nicotinamide despite not reaching statistical significance.
With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.
Using a cohort of more than 600 cognitively normal adults, the MIND diet failed to outperform a control diet of mild caloric restriction on several outcomes, including cognition and hippocampal volumes.
The associate professor of neurology at the Indiana University School of Medicine provided commentary on a study comparing traditional cognitive screening methods and the Linus Health Digital Clock and Recall test.
David Bates, PhD, chief executive officer and co-founder of Linus Health, provided insight on the transition of lecanemab to traditional approval, and how this decision impacts future care for Alzheimer disease.
In a cohort of nearly 800 frail adults and elderly patients with neuropsychiatric symptoms, pimavanserin showed similar rates of treatment-related adverse events and discontinuations because of TEAEs to placebo.
The clinical relevance of donanemab was demonstrated through a slowing of clinical decline, stability of clinical symptoms, lowered risk of advancement to next clinical stage, and lower risk of meaningful within-patient change.
Tenecteplase, a genetically modified molecule of alteplase, had similar benefit and safety as alteplase, and was not modified by baseline occlusion site.
A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.
After 4 years of treatment, more than 95% of infants on risdiplam maintained the ability to swallow, an aspect of everyday life that is commonly lost within 2 years in patients with SMA.
Over a 12-week period, the safety profile of a subcutaneous formulation of ocrelizumab was consistent with its original intravenous formulation, along with comparable MRI activity in the brain.
The AHEAD study will incorporate innovative features such as screening with biomarkers in blood, novel PET agents, sensitive cognitive outcome scales, dosing tailored to the level of amyloid in the brain, and recruitment approaches to ensure diverse representation.
While results of the study do not support the advancement of vatiquinone for the treatment of mitochondrial disease associated seizures, PTC Therapeutics continues to plan to advance the agent in Friedreich ataxia.
